871982-04-6

Basic information

• Product Name: [4-(2-benzothiazolyl)amino-5-chloro-2-fluorophenyl]acetic acid ethyl ester
• Synonyms: [4-(2-benzothiazolyl)amino-5-chloro-2-fluorophenyl]acetic acid ethyl ester
• CAS NO: 871982-04-6
• Molecular Weight: 364.828
• Mol File: 871982-04-6.mol

Chemical Properties

• CAS DataBase Reference: [4-(2-benzothiazolyl)amino-5-chloro-2-fluorophenyl]acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [4-(2-benzothiazolyl)amino-5-chloro-2-fluorophenyl]acetic acid ethyl ester(871982-04-6)
• EPA Substance Registry System: [4-(2-benzothiazolyl)amino-5-chloro-2-fluorophenyl]acetic acid ethyl ester(871982-04-6)

Safety Data

• Hazardous Substances Data: 871982-04-6(Hazardous Substances Data)

Upstream product

• 136-95-8 2-amino-benzthiazole 
• 2516-40-7 2-bromo-1,3-benzothiazole 
• 441717-78-8 ethyl 2-(4-amino-5-chloro-2-fluorophenyl)acetate 

Downstream Products

• 441715-00-0 C₂₈H₃₀ClF₂N₃O₄S 
• 441712-34-1 trans-4-[1-[[4-(2-benzothiazolyl)amino-5-chloro-2-fluorophenyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid 

Relevant articles and documents

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6- benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist

For the purpose of obtaining orally potent VLA-4 inhibitors, we have carried out structural modification of the (N′-phenylureido)phenyl group in compound 1, where the group was found to be attributed to poor pharmacokinetic profile in our previous research. Through modification, we have identified several compounds with both potent in vitro activity and improved oral exposure. In particular, compound 7e with 7-fluoro-2-(1-methyl-1H-indol-3- yl)-1,3-benzoxazolyl group as a novel replacement of the (N′-phenylureido) phenyl group significantly inhibited eosinophil infiltration into bronchoalveolar lavage fluid at 15 mg/kg in an Ascaris-antigen-induced murine bronchial inflammatory model, and its efficacy was comparable to that of the anti-mouse α4 antibody (R1-2).

VLA-4 INHIBITOR

A compound which selectively inhibits bonding between a ligand and α4β1 integrin (VLA-4); a process for producing the compound; and a medicine containing the compound. The compound is one represented by, e.g., the formula (I) or a salt thereof. Also provided is a preventive and/or therapeutic agent which contains the compound or salt as a major component and is effective against diseases attributable to cell adhesion, such as, e.g., inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory intestinal disease, and rejection reaction in transplantation. (In the formula, Y1 represents arylene, etc.; V1 represents aryl, etc.; and R11 to R14 each represents H, OH, halogeno, etc.)